338840.KQ Y-Biologics, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
03:46
Jan 15
Jan 15
Next-gen immuno-oncology platform targets Keytruda-resistant patients.
Y-Biologics is developing a next-generation immuno-oncology platform that combines a PD-1 antibody, an optimized cytokine, and a bispecific third axis to address the roughly 70% of patients who do not respond to Keytruda. Management expects AACR abstracts and clinical/preclinical data to attract global pharma interest, and the research director has been buying shares as a confidence signal. The company believes this multi-cytokine approach can surpass current PD-1xVEGF bispecifics.
HIGH
About 338840.KQ Investor Commentary
Across the available history and selected sources, Buzzberg tracks 338840.KQ (Y-Biologics, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Lee Kyung-ho.